Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I STZ plus S-1 for advanced gastroenteropancreatic neuroendocrine tumors
jRCTs031180247Phase 1Completed
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of streptozocin and tegafur in Gastroenteropancreatic Carcinoid Tumor. Primary endpoint: Dose-limiting toxicity (DLT) frequency. Started Mar 2017; status: completed.
02
Drugs
streptozocintegafur
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on jRCTs031180247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180247.